Acute Myeloid Leukaemia of Donor Cell Origin Developing 17 Years after Allogenic Hematopoietic Cell Transplantation for Acute Promyelocytic Leukaemia

Pilar Jiménez, J Carlos Alvarez, Pilar Garrido, J Lorente, Jorge Palacios, Francisco Ruiz-Cabello, Francisco Ruiz-Cabello
InternatIonal journal of BIomedIcal scIence   unpublished
Donor cell leukaemia (DcL) is a rare complication of allogenic hematopoietic cell transplantation (Hct). We report the case of a female patient with acute promyelocytic leukaemia (APL), FAb type M3, who developed acute myeloid leukaemia (AML) type M5 of donor origin 17 years after allogenic bone marrow trans-plantation (bMt) from her HLA-matched sister. Morphology and immunophenotyping showed differences with the initial leukaemia, and short tandem repeat (STR) analysis confirmed donor-type
more » ... rmed donor-type haematopoiesis. Interphase fluorescence in situ hybridisation (FISH) showed an 11q23 deletion. Given that the latency period between transplant and development of leukaemia was the longest reported to date, we discuss the mechanisms underlying delayed leukaemia onset. (Int J Biomed Sci 2012; 8 (4): 244-248)
fatcat:p7wwhjjdn5byfnqtxtraws4uli